Form 4: REVB Director Acquires 41,981 Shares

Revelation Biosciences Director Lakhmir S Chawla acquired 41,981 shares of common stock at $0.90 per share, increasing direct beneficial ownership to 57,667 shares.

Summary

• Lakhmir S Chawla, a Director of REVELATION BIOSCIENCES, INC. (REVB), acquired 41,981 shares of common stock.
• The transaction occurred on January 8, 2026, at a price of $0.90 per share.
• Following this acquisition, Mr. Chawla directly beneficially owns a total of 57,667 shares of common stock.
• The acquired shares are Restricted Stock Units under the 2021 Equity Incentive Plan and will vest quarterly over one year from the grant date.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is generally a positive indicator of insider confidence in the company's future, though the amount is relatively small in the context of a public company.

Positives

• A Director, Lakhmir S Chawla, increased his direct beneficial ownership in REVELATION BIOSCIENCES, INC. by acquiring 41,981 shares of common stock.
• Insider buying can signal confidence in the company's future prospects and valuation.
• The acquisition was made at a price of $0.90 per share.

Future Outlook

The acquired shares are Restricted Stock Units that will vest quarterly over one year from the date of grant, indicating a future vesting schedule for these equity awards.

Industry Context

This filing details an individual insider transaction and does not provide broader industry context or trends. Insider buying, particularly by a director, can sometimes be interpreted by the market as a positive signal, suggesting management's belief in the company's future performance, which is a common interpretation across various industries.

Comparison to Industry Standards

• Not applicable as this filing details an individual insider transaction rather than company performance or project results.

Related Party Transactions

• The acquisition of common stock by Lakhmir S Chawla, a Director of REVELATION BIOSCIENCES, INC., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May view the director's acquisition as a positive signal of confidence in the company's future, potentially influencing investor sentiment.
• Management: The transaction aligns the director's interests more closely with those of other shareholders.

Next Steps

• The acquired Restricted Stock Units will vest quarterly over one year from the date of grant (January 8, 2026).

Key Dates

Recommendation

While insider buying by a director is a positive signal, indicating confidence in the company's future, this single transaction of 41,981 shares at $0.90, while notable, is not substantial enough on its own to warrant a 'buy' recommendation without further fundamental analysis of Revelation Biosciences' broader financial health, strategic initiatives, and market position. It primarily reinforces a 'hold' stance for existing investors, suggesting no immediate negative catalysts from insider activity.

Keywords

Revelation Biosciences, REVB, Lakhmir S Chawla, Insider Trading, Form 4, Stock Acquisition, Director, Equity Incentive Plan, Restricted Stock Unit